Ilya Goldshleger Sells 3,100 Shares of RxSight, Inc. (NASDAQ:RXST) Stock

RxSight, Inc. (NASDAQ:RXST) insider Ilya Goldshleger sold 3,100 shares of RxSight stock in a transaction on Monday, September 23rd. The stock was sold at an average price of $52.67, for a total value of $163,277.00. Following the sale, the insider now directly owns 42,246 shares of the company’s stock, valued at $2,225,096.82. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Ilya Goldshleger also recently made the following trade(s):

• On Friday, September 20th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The stock was sold at an average price of $53.19, for a total value of $164,889.00.
• On Monday, August 5th, Ilya Goldshleger sold 9,000 shares of RxSight stock. The stock was sold at an average price of $39.25, for a total transaction of $353,250.00.

RxSight Price Performance

Shares of RxSight stock opened at $48.89 on Wednesday. The firm has a market cap of $1.81 billion, a price-to-earnings ratio of -38.80 and a beta of 1.22. RxSight, Inc. has a one year low of $20.66 and a one year high of $66.54. The stock’s 50-day moving average is $51.02 and its 200-day moving average is $53.90.

RxSight (NASDAQ:RXST) last released its quarterly earnings results on Monday, August 5th. The company reported ($0.16) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.06. RxSight had a negative return on equity of 19.33% and a negative net margin of 31.92%. The firm had revenue of $34.89 million during the quarter, compared to the consensus estimate of $32.33 million. During the same quarter in the prior year, the firm posted ($0.40) EPS. The business’s revenue was up 67.6% on a year-over-year basis. On average, equities analysts expect that RxSight, Inc. will post -0.81 EPS for the current year.

Analyst Ratings Changes

Several equities research analysts have weighed in on RXST shares. Oppenheimer cut their target price on shares of RxSight from $72.00 to $65.00 and set an “outperform” rating on the stock in a report on Tuesday, August 6th. BTIG Research lifted their target price on RxSight from $72.00 to $73.00 and gave the stock a “buy” rating in a report on Monday, July 15th. Wells Fargo & Company lowered their price target on RxSight from $68.00 to $54.00 and set an “overweight” rating for the company in a report on Tuesday, August 6th. Stifel Nicolaus cut their price objective on RxSight from $70.00 to $65.00 and set a “buy” rating on the stock in a report on Tuesday, August 6th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $66.00 price objective on shares of RxSight in a research report on Friday, September 13th. Seven investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $60.14.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the business. CWM LLC lifted its position in RxSight by 727.5% during the 2nd quarter. CWM LLC now owns 422 shares of the company’s stock worth $25,000 after buying an additional 371 shares in the last quarter. Quest Partners LLC acquired a new stake in shares of RxSight in the second quarter valued at about $41,000. Larson Financial Group LLC bought a new stake in RxSight during the first quarter worth about $51,000. Amalgamated Bank boosted its position in RxSight by 21.3% during the second quarter. Amalgamated Bank now owns 1,177 shares of the company’s stock valued at $71,000 after purchasing an additional 207 shares during the last quarter. Finally, Canada Pension Plan Investment Board bought a new position in RxSight in the second quarter valued at approximately $156,000. Institutional investors and hedge funds own 78.78% of the company’s stock.

RxSight Company Profile

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.